

Benjamin L Ebert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7275152/publications.pdf>

Version: 2024-02-01

334
papers

107,836
citations

2970

93
h-index

451

273
g-index

348
all docs

348
docs citations

348
times ranked

126287
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic Profiling of <i>DNMT3A</i> Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor. <i>Cancer Discovery</i> , 2022, 12, 220-235.	7.7	38
2	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. <i>Stroke</i> , 2022, 53, 788-797.	1.0	88
3	Association of clonal hematopoiesis with chronic obstructive pulmonary disease. <i>Blood</i> , 2022, 139, 357-368.	0.6	106
4	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	0.6	46
5	Repurposing the Damage Repair Protein Methyl Guanine Methyl Transferase as a Ligand Inducible Fusion Degron. <i>ACS Chemical Biology</i> , 2022, 17, 24-31.	1.6	4
6	<i>TP53</i> mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. <i>Blood Advances</i> , 2022, 6, 3201-3206.	2.5	8
7	Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for <i>CSNK1A1</i> in clonal expansion. <i>Blood Advances</i> , 2022, 6, 1780-1796.	2.5	7
8	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5.	2.8	49
9	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604.	5.8	22
10	Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. <i>Blood</i> , 2022, 139, 1246-1250.	0.6	15
11	Leukemia and Heart Disease. <i>JACC: CardioOncology</i> , 2022, 4, 50-52.	1.7	0
12	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. <i>Nature Medicine</i> , 2022, 28, 468-471.	15.2	19
13	Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the erythropoietic niche. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
14	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. <i>Science Advances</i> , 2022, 8, eabl6579.	4.7	36
15	Development of PDE6D and CK1 δ Degraders through Chemical Derivatization of FPFT-2216. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 747-756.	2.9	15
16	Genetics of smoking and risk of clonal hematopoiesis. <i>Scientific Reports</i> , 2022, 12, 7248.	1.6	25
17	Lenalidomide promotes the development of <i>TP53</i> -mutated therapy-related myeloid neoplasms. <i>Blood</i> , 2022, 140, 1753-1763.	0.6	56
18	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional <i>TP53</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1621-1629.	1.1	2

#	ARTICLE	IF	CITATIONS
19	<i>TET2</i> -mutant clonal hematopoiesis and risk of gout. <i>Blood</i> , 2022, 140, 1094-1103.	0.6	57
20	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
21	Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state. <i>Nature Communications</i> , 2022, 13, .	5.8	15
22	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
23	Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
24	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. <i>Journal of Internal Medicine</i> , 2022, 292, 262-277.	2.7	7
25	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
26	Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. <i>Circulation</i> , 2021, 143, 410-423.	1.6	87
27	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. <i>Cell Reports</i> , 2021, 34, 108532.	2.9	54
28	Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. <i>JCI Insight</i> , 2021, 6, .	2.3	39
29	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021, 106, 1330-1342.	1.7	19
30	The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. <i>Nature</i> , 2021, 592, 296-301.	13.7	236
31	Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 250-265.	2.6	19
32	Cancer therapies based on targeted protein degradation â€” lessons learned with lenalidomide. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 401-417.	12.5	69
33	Modeling and targeting of erythroleukemia by hematopoietic genome editing. <i>Blood</i> , 2021, 137, 1628-1640.	0.6	25
34	<i>CBL</i> mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. <i>Blood</i> , 2021, 137, 2209-2220.	0.6	18
35	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. <i>Nature Medicine</i> , 2021, 27, 1012-1024.	15.2	109
36	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. <i>Blood Cancer Discovery</i> , 2021, 2, 500-517.	2.6	17

#	ARTICLE	IF	CITATIONS
37	Whole exome sequencing of a breast tumor in a patient with Diamond Blackfan anemia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 89, 102566.	0.6	0
38	Association of Clonal Hematopoiesis With Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 42-52.	1.2	101
39	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 2982-2986.	2.5	45
40	Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2021, 6, 1069.	3.0	43
41	Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	132
42	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021, 106, 651-654.	1.7	4
43	Congenital X-linked Neutropenia with Myelodysplasia and Somatic Tetraploidy due to a Germline Mutation in SEPT6. <i>American Journal of Hematology</i> , 2021, , .	2.0	1
44	Distinction of lymphoid and myeloid clonal hematopoiesis. <i>Nature Medicine</i> , 2021, 27, 1921-1927.	15.2	130
45	<i>Dnmt3a</i> -mutated clonal hematopoiesis promotes osteoporosis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	81
46	Germline Runx1 Mutations Induce Inflammation in Hematopoietic Stem and Progenitor Cells and Predispose to Hematologic Malignancies. <i>Blood</i> , 2021, 138, 2201-2201.	0.6	0
47	Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. <i>Blood</i> , 2021, 138, 2830-2830.	0.6	1
48	The Association between Clonal Hematopoiesis and Gout. <i>Blood</i> , 2021, 138, 595-595.	0.6	4
49	Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 1127-1127.	0.6	0
50	Obesity-Induced Inflammation Co-Operates with Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutants to Promote Leukemia Development and Cardiovascular Disease. <i>Blood</i> , 2021, 138, 1094-1094.	0.6	6
51	Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2021, 138, 1091-1091.	0.6	1
52	Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). <i>Leukemia</i> , 2020, 34, 404-415.	3.3	16
53	Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS. <i>Leukemia and Lymphoma</i> , 2020, 61, 728-731.	0.6	5
54	A new opening on aortic stenosis: predicting prognosis with clonal haematopoiesis. <i>European Heart Journal</i> , 2020, 41, 940-942.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Clonal hematopoiesis as a model for premalignant changes during aging. <i>Experimental Hematology</i> , 2020, 83, 48-56.	0.2	56
56	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reinduction chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, 245-250.	2.0	13
57	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.	0.6	15
58	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 1027-1033.	1.5	20
59	Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	26
60	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. <i>Nature</i> , 2020, 586, 763-768.	13.7	376
61	CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia. <i>Cell Reports</i> , 2020, 31, 107684.	2.9	28
62	Small-molecule-induced polymerization triggers degradation of BCL6. <i>Nature</i> , 2020, 588, 164-168.	13.7	143
63	<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. <i>Blood</i> , 2020, 136, 2812-2823.	0.6	113
64	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
65	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
66	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2020, 135, 1548-1559.	0.6	58
67	The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. <i>Nature</i> , 2020, 585, 293-297.	13.7	219
68	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 1729-1738.	0.6	80
69	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
70	The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor. <i>JAMA Cardiology</i> , 2020, 5, 958.	3.0	33
71	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
72	The impact of the COVID-19 pandemic on cancer care. <i>Nature Cancer</i> , 2020, 1, 565-567.	5.7	392

#	ARTICLE	IF	CITATIONS
73	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020, 37, 104-122.e12.	7.7	267
74	Rapid and deep-scale ubiquitylation profiling for biology and translational research. <i>Nature Communications</i> , 2020, 11, 359.	5.8	75
75	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.	2.5	8
76	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. <i>Blood</i> , 2020, 136, 32-33.	0.6	2
77	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). <i>Neuro-Oncology</i> , 2020, 22, iii297-iii297.	0.6	0
78	An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation. <i>Blood Advances</i> , 2020, 4, 4679-4692.	2.5	1
79	Using an in-Vivo Degron-Based Approach to Interrogate Dependencies of Serially Acquired Mutations - Including DNMT3a-R882 and NPM1c - in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
80	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
81	Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial. <i>Blood</i> , 2020, 136, 10-10.	0.6	0
82	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	6.0	265
83	Clonal Hematopoiesis. <i>Journal of the American College of Cardiology</i> , 2019, 74, 567-577.	1.2	150
84	Clonal hematopoiesis in human aging and disease. <i>Science</i> , 2019, 366, .	6.0	590
85	CHIPing Away at Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 112, 10-11.	3.0	0
86	Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	29
87	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. <i>Cancer Cell</i> , 2019, 35, 283-296.e5.	7.7	71
88	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). <i>Neuro-Oncology</i> , 2019, 21, ii70-ii71.	0.6	0
89	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 400-410.	1.8	58
90	Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. <i>Blood</i> , 2019, 134, 160-170.	0.6	41

#	ARTICLE	IF	CITATIONS
91	Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background. <i>Blood</i> , 2019, 133, 2610-2614.	0.6	11
92	Impaired human hematopoiesis due to a cryptic intronic GATA1 splicing mutation. <i>Journal of Experimental Medicine</i> , 2019, 216, 1050-1060.	4.2	27
93	Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. <i>Cell Chemical Biology</i> , 2019, 26, 711-723.e14.	2.5	82
94	Clonal Hematopoiesis of Indeterminate Potential. <i>Journal of Clinical Oncology</i> , 2019, 37, 419-422.	0.8	18
95	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019, 51, 694-704.	9.4	97
96	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	2.5	52
97	CHIPping Away at the Pathogenesis of Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 5.	3.0	8
98	Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. <i>Leukemia</i> , 2019, 33, 1759-1772.	3.3	35
99	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
100	Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies. <i>Blood</i> , 2019, 134, 563-563.	0.6	1
101	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 675-675.	0.6	17
102	Intergenerational epigenetic inheritance of cancer susceptibility in mammals. <i>ELife</i> , 2019, 8, .	2.8	43
103	Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis. <i>ELife</i> , 2019, 8, .	2.8	14
104	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradors of Oncoproteins. <i>Blood</i> , 2019, 134, 318-318.	0.6	0
105	High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster. <i>Blood</i> , 2019, 134, 3720-3720.	0.6	1
106	Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level. <i>Blood</i> , 2019, 134, 559-559.	0.6	0
107	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. <i>Blood</i> , 2019, 134, 4271-4271.	0.6	0
108	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	299

#	ARTICLE	IF	CITATIONS
109	A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. <i>Leukemia</i> , 2018, 32, 1493-1499.	3.3	39
110	Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. <i>Haematologica</i> , 2018, 103, 626-633.	1.7	20
111	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 254-261.	2.0	12
112	Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 379, 1873-1874.	13.9	6
113	<i>Jak</i> -ing Up the Plaque's Lipid Core and Even More. <i>Circulation Research</i> , 2018, 123, 1180-1182.	2.0	9
114	Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. <i>Science</i> , 2018, 362, .	6.0	320
115	Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. <i>Annals of Internal Medicine</i> , 2018, 169, 116.	2.0	26
116	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. <i>Blood</i> , 2018, 132, 1095-1105.	0.6	160
117	Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. <i>Blood</i> , 2018, 132, 1535-1544.	0.6	71
118	Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. <i>Blood</i> , 2018, 132, 1293-1303.	0.6	97
119	Predicting progression to AML. <i>Nature Medicine</i> , 2018, 24, 904-906.	15.2	22
120	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. <i>Cancer Cell</i> , 2018, 34, 225-241.e8.	7.7	162
121	CHIP (Clonal Hematopoiesis of Indeterminate Potential). <i>Circulation</i> , 2018, 138, 666-668.	1.6	71
122	CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. <i>Cancer Discovery</i> , 2018, 8, 884-897.	7.7	53
123	Generations of physician-scientists. <i>Journal of Clinical Investigation</i> , 2018, 128, 4208-4212.	3.9	1
124	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	0.6	6
125	Discovery of a Novel Mechanism of Resistance to Thalidomide Derivatives. <i>Blood</i> , 2018, 132, 949-949.	0.6	1
126	Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice. <i>Blood</i> , 2018, 132, 745-745.	0.6	21

#	ARTICLE	IF	CITATIONS
127	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. <i>Blood</i> , 2018, 132, 1446-1446.	0.6	2
128	Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. <i>ELife</i> , 2018, 7, .	2.8	314
129	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018, 132, 817-817.	0.6	0
130	SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition. <i>Blood</i> , 2018, 132, 107-107.	0.6	0
131	Multiplex CRISPR/Cas9-Based Genome Editing of Mouse Hematopoietic Stem Cells Recapitulates Acute Erythroid Leukemia and Identifies Therapeutic Targets. <i>Blood</i> , 2018, 132, 5-5.	0.6	0
132	Congenital X-Linked Myelodysplasia with Tetraploidy Is Associated with De Novo Germline C-Terminal Mutation of SEPT6, a Septin Filament Protein. <i>Blood</i> , 2018, 132, 644-644.	0.6	0
133	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. <i>Blood</i> , 2018, 132, 1367-1367.	0.6	0
134	CXCR4 Has a CXCL12-Independent Essential Role in MLL-AF9 Driven Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 774-774.	0.6	0
135	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	0.8	339
136	Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with <i>TP53</i> mutations. <i>EMBO Molecular Medicine</i> , 2017, 9, 498-507.	3.3	86
137	Doubling Down on Mutant RAS Can MEK or Break Leukemia. <i>Cell</i> , 2017, 168, 749-750.	13.5	3
138	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	13.9	586
139	Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	87
140	Gli1 + Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. <i>Cell Stem Cell</i> , 2017, 20, 785-800.e8.	5.2	195
141	Introduction to a review series on precision hematology. <i>Blood</i> , 2017, 130, 408-409.	0.6	6
142	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 111-121.	13.9	1,738
143	<i>NPM1</i> mutation but not <i>RUNX1</i> mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. <i>American Journal of Hematology</i> , 2017, 92, E123-E124.	2.0	11
144	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375

#	ARTICLE	IF	CITATIONS
145	The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. <i>Blood</i> , 2017, 129, 497-508.	0.6	65
146	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. <i>Cell Stem Cell</i> , 2017, 21, 547-555.e8.	5.2	71
147	Clonal Hematopoiesis and Atherosclerosis. <i>New England Journal of Medicine</i> , 2017, 377, 1400-1402.	13.9	33
148	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. <i>Blood</i> , 2017, 130, 2631-2641.	0.6	102
149	Vitamin C regulates stem cells and cancer. <i>Nature</i> , 2017, 549, 462-464.	13.7	11
150	Utility of CRISPR/Cas9 systems in hematology research. <i>Experimental Hematology</i> , 2017, 54, 1-3.	0.2	11
151	The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. <i>Nature Reviews Cancer</i> , 2017, 17, 5-19.	12.8	542
152	Clonal hematopoiesis. <i>Seminars in Hematology</i> , 2017, 54, 43-50.	1.8	100
153	Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NF κ B-dependent differentiation of AML cells. <i>Blood Advances</i> , 2017, 1, 2046-2057.	2.5	35
154	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
155	Introduction to Genomics in Hematologic Malignancy. <i>Journal of Clinical Oncology</i> , 2017, 35, 927-928.	0.8	2
156	Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 968-974.	0.8	117
157	Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. <i>ELife</i> , 2017, 6, .	2.8	66
158	Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. <i>Cell</i> , 2016, 165, 303-316.	13.5	200
159	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227
160	Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. <i>Cancer Cell</i> , 2016, 30, 404-417.	7.7	318
161	An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites. <i>Journal of Hematology and Oncology</i> , 2016, 9, 4.	6.9	35
162	Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. <i>Nature Medicine</i> , 2016, 22, 288-297.	15.2	191

#	ARTICLE	IF	CITATIONS
163	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. <i>Cancer Cell</i> , 2016, 29, 214-228.	7.7	216
164	Genome-Scale Screen Reveals Genes Required for Lenalidomide-Mediated Degradation of Aiolos By CRL4-CRBN. <i>Blood</i> , 2016, 128, 5139-5139.	0.6	2
165	Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation. <i>Blood</i> , 2016, 128, 633-633.	0.6	1
166	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 69-69.	0.6	2
167	Synthetic Lethal Interactions of MDS-Associated Spliceosomal Gene Mutations Identifies the Basis for Their Mutual Exclusivity. <i>Blood</i> , 2016, 128, 961-961.	0.6	6
168	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	0.6	3
169	Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 3193-3193.	0.6	0
170	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. <i>Blood</i> , 2016, 128, 739-739.	0.6	0
171	Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. <i>Blood</i> , 2015, 125, 327-335.	0.6	86
172	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015, 125, 1367-1376.	0.6	747
173	Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. <i>Blood</i> , 2015, 125, 3668-3669.	0.6	20
174	EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. <i>Blood</i> , 2015, 126, 1930-1939.	0.6	76
175	The novel mechanism of lenalidomide activity. <i>Blood</i> , 2015, 126, 2366-2369.	0.6	143
176	Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. <i>American Journal of Hematology</i> , 2015, 90, 624-628.	2.0	20
177	Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. <i>Cell Reports</i> , 2015, 10, 755-770.	2.9	21
178	Lenalidomide induces ubiquitination and degradation of CK1 α in del(5q) MDS. <i>Nature</i> , 2015, 523, 183-188.	18.7	648
179	Charting the Splice-Routes to MDS. <i>Cancer Cell</i> , 2015, 27, 607-609.	7.7	9
180	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.	0.6	1,493

#	ARTICLE	IF	CITATIONS
181	Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. <i>Genome Research</i> , 2015, 25, 1860-1872.	2.4	614
182	DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. <i>Clinical Chemistry</i> , 2015, 61, 1354-1362.	1.5	9
183	Drosophila glucone screening identifies Ck1alpha as a regulator of mammalian glucose metabolism. <i>Nature Communications</i> , 2015, 6, 7102.	5.8	71
184	Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. <i>Current Opinion in Cell Biology</i> , 2015, 37, 61-67.	2.6	18
185	Mutations in G protein $\hat{2}$ subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015, 21, 71-75.	15.2	106
186	Perivascular Gli1+ Progenitors Are Key Contributors to Injury-Induced Organ Fibrosis. <i>Cell Stem Cell</i> , 2015, 16, 51-66.	5.2	738
187	Expression of Sf3b1-K700E in Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function. <i>Blood</i> , 2015, 126, 366-366.	0.6	1
188	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , 2015, 126, 907-907.	0.6	85
189	A Novel Conditional Knockout of the Diamond Blackfan Anemia Gene Rpl11 Shows Failure of Erythropoiesis, a Marked Increase in BFU-E Progenitors By Phenotype That Proliferate Poorly in Culture, and Activation of p53 Target Genes. <i>Blood</i> , 2015, 126, 1205-1205.	0.6	0
190	Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells. <i>Blood</i> , 2015, 126, 1643-1643.	0.6	2
191	Calmodulin Inhibition Rescues the Effects of Ribosomal Protein Deficiency in in Vitro and In Vivo Diamond Blackfan Anemia Models. <i>Blood</i> , 2015, 126, 672-672.	0.6	0
192	Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression. <i>Blood</i> , 2015, 126, 4112-4112.	0.6	0
193	Clonal Diversity and Mutated Genes in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, SCI-3-SCI-3.	0.6	0
194	SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response. <i>Blood</i> , 2015, 126, 2626-2626.	0.6	0
195	Cooperating Effect of Rps14, Csnk1a1 and miRNA145/miRNA146a Haploinsufficiency in the Activation of the Innate Immune System in Del(5q) MDS. <i>Blood</i> , 2015, 126, 356-356.	0.6	0
196	Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis. <i>PLoS ONE</i> , 2014, 9, e96209.	1.1	31
197	Musashi-2 controls cell fate, lineage bias, and TGF- $\hat{2}$ signaling in HSCs. <i>Journal of Experimental Medicine</i> , 2014, 211, 71-87.	4.2	136
198	Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q $\hat{2}$ syndrome in a <sc>TP</sc>53 $\hat{2}$ independent way. <i>British Journal of Haematology</i> , 2014, 167, 524-528.	1.2	27

#	ARTICLE	IF	CITATIONS
199	Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2014, 211, 605-612.	4.2	79
200	Lenalidomide induces degradation of IKZF1 and IKZF3. <i>Oncolmmunology</i> , 2014, 3, e941742.	2.1	63
201	Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. <i>New England Journal of Medicine</i> , 2014, 371, 2488-2498.	13.9	3,474
202	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	0.8	359
203	The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders. <i>Leukemia and Lymphoma</i> , 2014, 55, 491-500.	0.6	51
204	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2014, 5, 3469.	5.8	171
205	Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. <i>Blood</i> , 2014, 123, e123-e133.	0.6	337
206	Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. <i>Science</i> , 2014, 343, 84-87.	6.0	4,210
207	Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. <i>Science</i> , 2014, 343, 301-305.	6.0	1,371
208	Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. <i>Cancer Cell</i> , 2014, 26, 509-520.	7.7	158
209	Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. <i>Nature Biotechnology</i> , 2014, 32, 1262-1267.	9.4	1,351
210	MDS Is a Stem Cell Disorder After All. <i>Cancer Cell</i> , 2014, 25, 713-714.	7.7	16
211	Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. <i>Nature Biotechnology</i> , 2014, 32, 941-946.	9.4	477
212	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , 2014, 124, 2705-2712.	0.6	486
213	Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q). <i>Blood</i> , 2014, 124, 4-4.	0.6	19
214	Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation. <i>Blood</i> , 2014, 124, 4615-4615.	0.6	1
215	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. <i>Blood</i> , 2014, 124, 532-532.	0.6	6
216	Toll-like Receptor 1 Is a Candidate Therapeutic Target in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5782-5782.	0.6	4

#	ARTICLE	IF	CITATIONS
217	Loss of TET2 Function in Myelodysplastic Syndrome Results in Intragenic Hypermethylation and Alterations in mRNA Splicing. <i>Blood</i> , 2014, 124, 775-775.	0.6	2
218	Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated Erythropoiesis and a Stem Cell Disadvantage. <i>Blood</i> , 2014, 124, 828-828.	0.6	3
219	Ontogeny-Specific Patterns of Genetic Alterations in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 18-18.	0.6	0
220	Reduced Protein Synthesis and p53 Activation in Late-Stage Erythroblasts Mediate the Erythroid Differentiation Defect in Mice with Ribosomal Protein S14 Haploinsufficiency. <i>Blood</i> , 2014, 124, 1892-1892.	0.6	0
221	A Proteomics Screen Identifies MDM2 Binding Partners Specific to Ribosomal Protein Haploinsufficiency. <i>Blood</i> , 2014, 124, 1597-1597.	0.6	3
222	Clonal Hematopoiesis with Somatic Mutations Is a Common, Age-Related Condition Associated with Adverse Outcomes. <i>Blood</i> , 2014, 124, 840-840.	0.6	1
223	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. <i>Blood</i> , 2014, 124, 3262-3262.	0.6	0
224	The Recq15 Helicase Is a Novel Downstream Target of Jak2V617F and Maintains Genome Stability in Response to Replication Stress. <i>Blood</i> , 2014, 124, 822-822.	0.6	21
225	Sinister Symbiosis: Pathological Hematopoietic-Stromal Interactions in CML. <i>Cell Stem Cell</i> , 2013, 13, 257-258.	5.2	4
226	Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. <i>Nature Chemical Biology</i> , 2013, 9, 840-848.	3.9	103
227	(<i>l</i>)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. <i>Science</i> , 2013, 339, 1621-1625.	6.0	624
228	Deletion 5q MDS: Molecular and therapeutic implications. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 365-375.	0.7	44
229	Molecular Pathophysiology of Myelodysplastic Syndromes. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013, 8, 21-47.	9.6	78
230	Macrophages support pathological erythropoiesis in polycythemia vera and β -thalassemia. <i>Nature Medicine</i> , 2013, 19, 437-445.	15.2	202
231	In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. <i>Cancer Cell</i> , 2013, 24, 45-58.	7.7	144
232	Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- γ in a murine model of polycythemia vera. <i>Blood</i> , 2013, 121, 3692-3702.	0.6	140
233	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 109-109.	0.6	5
234	Functional Defects In Neutrophils Derived From Ezh2 Null Mice. <i>Blood</i> , 2013, 122, 1556-1556.	0.6	5

#	ARTICLE	IF	CITATIONS
235	Msi2 Directly Regulates The TGF- β 2 Signaling Pathway and Myeloid Lineage Bias In Hematopoietic Stem Cells. <i>Blood</i> , 2013, 122, 468-468.	0.6	0
236	Ex Vivo expansion Of Umbilical Cord Blood CD34+ Cells Under Hypoxic Conditions Using Novel Compound#999 With Cytokines. <i>Blood</i> , 2013, 122, 4508-4508.	0.6	1
237	Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3. <i>Blood</i> , 2013, 122, LBA-5-LBA-5.	0.6	1
238	Critical Role Of Casein Kinase (Ck)1 \pm Heterozygote Gene Inactivation In The Clonal Advantage Of Hematopoietic Stem Cells In Del(5q) MDS. <i>Blood</i> , 2013, 122, 98-98.	0.6	0
239	Tet2 Loss Accelerates The Myeloproliferative Neoplasm (MPN) Phenotype Of Jak2V617F Knockin Mice But Is Insufficient To Cause Leukemic Transformation. <i>Blood</i> , 2013, 122, 4095-4095.	0.6	0
240	Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. <i>Blood</i> , 2012, 120, 166-172.	0.6	65
241	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2012, 30, 3376-3382.	0.8	419
242	Implantable microenvironments to attract hematopoietic stem/cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19638-19643.	3.3	93
243	Myeloproliferative Neoplasm Animal Models. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1065-1081.	0.9	33
244	L-leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. <i>Blood</i> , 2012, 120, 2214-2224.	0.6	149
245	Heterodimeric JAK \leftrightarrow STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. <i>Nature</i> , 2012, 489, 155-159.	13.7	320
246	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 311-311.	0.6	3
247	Calmodulin Inhibition Rescues the Effects of Ribosomal Protein Deficiency by Modulating p53 Activity in Models of Diamond Blackfan Anemia. <i>Blood</i> , 2012, 120, 512-512.	0.6	3
248	Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma. <i>Blood</i> , 2012, 120, 571-571.	0.6	1
249	Overexpression of Ribosomal Proteins Is Insufficient for p53 Pathway Induction in Cell Lines and Primary CD34+ Cells. <i>Blood</i> , 2012, 120, 3479-3479.	0.6	0
250	Inhibition of the CRBN-DDB1-CUL4-ROC1 E3 Ubiquitin Ligase Mediates the Anti-Proliferative and Immunomodulatory Properties of Lenalidomide. <i>Blood</i> , 2012, 120, 919-919.	0.6	1
251	Depletion of Jak2V617F MPN Stem Cells by IFN γ in a Murine Model of Polycythemia Vera. <i>Blood</i> , 2012, 120, 806-806.	0.6	0
252	Casein Kinase 1 Alpha Maintains Normal and Leukemic Stem Cells by Regulating p53 Activity. <i>Blood</i> , 2012, 120, 209-209.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Removal of Macrophages From the Erythroid Niche Impairs Stress Erythropoiesis but Improves Pathophysiology of Polycythemia Vera and Beta-Thalassemia. <i>Blood</i> , 2012, 120, 81-81.	0.6	0
254	Direct RNA Target Analysis Identifies Signatures That Define Msi2's Role in Sustaining HSC Cell Fate.. <i>Blood</i> , 2012, 120, 2324-2324.	0.6	0
255	Identification of Small Molecules Selectively Targeting Leukemic Stem Cells within Their Stromal Niche. <i>Blood</i> , 2012, 120, 413-413.	0.6	0
256	Discovery Science and Integrating Molecular Diagnosis into Clinical Practice. <i>Blood</i> , 2012, 120, SCI-31-SCI-31.	0.6	0
257	L-Leucine Improves the Anemia of DBA and the 5q- Syndrome Via Activation of the mTOR Pathway in a p53-Independent Manner. <i>Blood</i> , 2012, 120, 1257-1257.	0.6	0
258	Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells. <i>Blood</i> , 2012, 120, 208-208.	0.6	0
259	Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing. <i>Science</i> , 2011, 334, 993-996.	6.0	281
260	Stem cell gene expression programs influence clinical outcome in human leukemia. <i>Nature Medicine</i> , 2011, 17, 1086-1093.	15.2	894
261	Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis. <i>Cell</i> , 2011, 144, 296-309.	13.5	843
262	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2011, 364, 2496-2506.	13.9	1,444
263	Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. <i>Blood</i> , 2011, 117, 2567-2576.	0.6	347
264	Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. <i>Blood</i> , 2011, 118, 2296-2304.	0.6	72
265	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5qâ syndrome. <i>Blood</i> , 2011, 118, 4666-4673.	0.6	97
266	The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. <i>Blood</i> , 2011, 117, 3421-3429.	0.6	239
267	Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome. <i>Seminars in Oncology</i> , 2011, 38, 621-626.	0.8	62
268	Ribosome defects in disorders of erythropoiesis. <i>International Journal of Hematology</i> , 2011, 93, 144-149.	0.7	37
269	Human tumors instigate granulins-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 784-799.	3.9	177
270	Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy. <i>Blood</i> , 2011, 118, 122-122.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Msi2 Maintains Normal Hematopoietic Stem Cell Self-Renewal. <i>Blood</i> , 2011, 118, 222-222.	0.6	1
272	Evaluating Clonal Dominance in a Murine Knock-in Model of Jak2V617F MPN. <i>Blood</i> , 2011, 118, 614-614.	0.6	1
273	Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. <i>Blood</i> , 2011, 118, 969-969.	0.6	5
274	Selective Targeting of Leukemic Over Normal Stem Cells by the Serotonin Receptor Antagonist SB-216641. <i>Blood</i> , 2011, 118, 1884-1884.	0.6	0
275	Oncogene Cooperativity Analysis Reveals a Novel Set of Genes That Regulate the In Vivo Growth and Survival of Leukemia Stem Cells. <i>Blood</i> , 2011, 118, 553-553.	0.6	0
276	Distinct Metabolic Dependency of Normal and Leukemic Cells in a Mouse Model. <i>Blood</i> , 2011, 118, 759-759.	0.6	0
277	Induction of Fetal Hemoglobin by Inactivation of HDAC1 or HDAC2 without Altering Cellular Proliferation. <i>Blood</i> , 2011, 118, 354-354.	0.6	0
278	Niche-Based Screening Reveals Leukemia Stem Cell Specific Therapeutics. <i>Blood</i> , 2011, 118, 760-760.	0.6	0
279	L-Leucine Improves the Anemia of the 5q- Syndrome Via Activation of the mTOR (mammalian target of) Tj ETQq1 1 0.784314 0.6 BT /O	0.6	0
280	In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. <i>Blood</i> , 2011, 118, 758-758.	0.6	0
281	The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. <i>Blood</i> , 2010, 115, 3489-3497.	0.6	88
282	Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. <i>Cancer Cell</i> , 2010, 17, 584-596.	7.7	324
283	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010, 463, 899-905.	13.7	3,331
284	Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. <i>Nature</i> , 2010, 464, 852-857.	13.7	980
285	Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. <i>Nature Medicine</i> , 2010, 16, 903-908.	15.2	338
286	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. <i>Nature Medicine</i> , 2010, 16, 1147-1151.	15.2	448
287	Ribosomopathies: human disorders of ribosome dysfunction. <i>Blood</i> , 2010, 115, 3196-3205.	0.6	678
288	Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12617-12622.	3.3	179

#	ARTICLE	IF	CITATIONS
289	Preface. Hematology/Oncology Clinics of North America, 2010, 24, xiii-xvi.	0.9	3
290	The Genetic Basis of Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 295-315.	0.9	28
291	Genetic deletions in AML and MDS. Best Practice and Research in Clinical Haematology, 2010, 23, 457-461.	0.7	27
292	Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q- Syndrome) with L-Leucine Results In An Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway?. Blood, 2010, 116, 195-195.	0.6	1
293	Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. Blood, 2010, 116, 300-300.	0.6	0
294	Reactivation of Silenced Human HbF In Adult Mice by Inactivation of BCL11A. Blood, 2010, 116, 643-643.	0.6	0
295	MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. Blood, 2010, 116, 1865-1865.	0.6	0
296	Characterizing the Disease-Initiating Cell Population In a Murine Model of Jak2V617F+ Myeloproliferative Neoplasm. Blood, 2010, 116, 317-317.	0.6	9
297	Therapeutic potential of targeting haploinsufficient genes in cancer. Pediatric Blood and Cancer, 2009, 53, 131-132.	0.8	2
298	Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia, 2009, 23, 1252-1256.	3.3	87
299	A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nature Genetics, 2009, 41, 455-459.	9.4	322
300	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 2009, 114, 144-147.	0.6	661
301	Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome.. Blood, 2009, 114, 947-947.	0.6	7
302	Lineage-Specific Activation of p53 in Response to Ribosomal Haploinsufficiency in Human Bone Marrow Cells.. Blood, 2009, 114, 948-948.	0.6	0
303	Ribosome Dysfunction and Ineffective Hematopoiesis.. Blood, 2009, 114, SCI-11-SCI-11.	0.6	0
304	Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.. Blood, 2009, 114, 247-247.	0.6	0
305	Lenalidomide and Dexamethasone Promote Erythropoiesis in Both Normal and RPS14 and RPS19 shRNA Infected Human CD34+ Cells: Implications for Therapy of Myelodysplastic Syndrome and Diamond-Blackfan Anemia.. Blood, 2009, 114, 1092-1092.	0.6	0
306	Leukemic and Normal Stem Cell Transcriptional Signatures Determined by Functional Assays Are Predictive of the Overall Survival of AML Patients.. Blood, 2009, 114, 389-389.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Integrative Genomic Analysis of HIV-Specific CD8+ T Cells Reveals That PD-1 Inhibits T Cell Function by Upregulating the AP-1 Transcription Factor BATF.. Blood, 2009, 114, 916-916.	0.6	0
308	Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature, 2008, 451, 335-339.	13.7	850
309	Small-Molecule Inhibitors of HIF-2a Translation Link Its 5'UTR Iron-Responsive Element to Oxygen Sensing. Molecular Cell, 2008, 32, 838-848.	4.5	175
310	MicroRNA-Mediated Control of Cell Fate in Megakaryocyte-Erythrocyte Progenitors. Developmental Cell, 2008, 14, 843-853.	3.1	336
311	An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome. PLoS Medicine, 2008, 5, e35.	3.9	145
312	Downregulation of Ribosomal Proteins Is Seen in Non 5q- MDS. Blood, 2008, 112, 854-854.	0.6	6
313	Integrative Analysis of Genomic Aberration and Gene Expression Suggests That MPD with Loss of Heterozygosity or Gain of Chromosome 9 Represents a Distinct Entity. Blood, 2008, 112, 3735-3735.	0.6	5
314	NFIB: A Gene Consistently Upregulated in MPD and Frequently Co-Amplified with JAK2V617F Augments Growth of Erythropoietin Dependent Cells. Blood, 2008, 112, 3727-3727.	0.6	0
315	Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5959-5964.	3.3	126
316	pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF- κ B Agonist Card9 by CK2. Molecular Cell, 2007, 28, 15-27.	4.5	163
317	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Cancer Cell, 2007, 12, 501-513.	7.7	174
318	Identification of RPS14 as the 5q-Syndrome Gene by RNA Interference Screen.. Blood, 2007, 110, 1-1.	0.6	16
319	Failure to prolyl hydroxylate hypoxia-inducible factor $\hat{\pm}$ phenocopies VHL inactivation in vivo. EMBO Journal, 2006, 25, 4650-4662.	3.5	210
320	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Medicine, 2006, 3, e270.	3.9	1,222
321	All Memory Lymphocytes Share a Common Differentiation Program.. Blood, 2006, 108, 865-865.	0.6	0
322	An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood, 2005, 105, 4620-4626.	0.6	83
323	Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15545-15550.	3.3	38,922
324	MicroRNA expression profiles classify human cancers. Nature, 2005, 435, 834-838.	13.7	8,931

#	ARTICLE	IF	CITATIONS
325	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. <i>Cancer Cell</i> , 2005, 7, 387-397.	7.7	2,695
326	Characterization of Distinct Molecular Signatures in Myeloproliferative Diseases with the JAK2V617F Mutation and Wild Type JAK2.. <i>Blood</i> , 2005, 106, 119-119.	0.6	0
327	Transcriptional Mapping of T Cell Memory Reveals That Chronic Viral Infection Arrests Memory Differentiation.. <i>Blood</i> , 2005, 106, 328-328.	0.6	2
328	Use of Temozolomide with Other Cytotoxic Chemotherapy in the Treatment of Patients with Recurrent Brain Metastases from Lung Cancer. <i>Oncologist</i> , 2003, 8, 69-75.	1.9	50
329	Some Unusual Paraneoplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2003, 21, 2624-2625.	0.8	8
330	Regulation of Transcription by Hypoxia Requires a Multiprotein Complex That Includes Hypoxia-Inducible Factor 1, an Adjacent Transcription Factor, and p300/CREB Binding Protein. <i>Molecular and Cellular Biology</i> , 1998, 18, 4089-4096.	1.1	254
331	Diphenylene Iodonium Inhibits the Induction of Erythropoietin and Other Mammalian Genes by Hypoxia. Implications for the Mechanism of Oxygen Sensing. <i>FEBS Journal</i> , 1995, 234, 92-99.	0.2	86
332	Hypoxia and Mitochondrial Inhibitors Regulate Expression of Glucose Transporter-1 via Distinct Cis-acting Sequences. <i>Journal of Biological Chemistry</i> , 1995, 270, 29083-29089.	1.6	449
333	Hypoxic Regulation of Lactate Dehydrogenase A. <i>Journal of Biological Chemistry</i> , 1995, 270, 21021-21027.	1.6	471
334	Blood's life history traced through genomic scars. <i>Nature</i> , 0, , .	13.7	0